NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Nextracker Inc. (NASDAQ:NXT)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the impact of project delays on Nextracker's business, financial results, and prospects was far more severe than represented to investors; (ii) permitting and interconnection delays had materially impaired Nextracker's ability to convert backlog into revenue at historical conversion rates; (iii) Nextracker had been unable to offset the negative impact from project delays through increased client demand and the purported ability to pull forward its other projects in the manner represented by the Company; (iv) Nextracker did not possess the competitive advantages which purportedly shielded it from industry-wide headwinds or the ability to effectively offset the adverse effects of project delays as claimed by the Company; and (v) consequently, the Company lacked a reasonable basis for their positive statements about Nextracker's business, financial results, and prospects.
If you are an NXT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Revance Therapeutics, Inc. (NASDAQ:RVNC)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information. In January 2020, Revance entered into a distribution agreement with Teoxane SA, pursuant to which Teoxane granted Revance the exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
In August 2024, Revance and Crown Laboratories, Inc., a privately held marketer and manufacturer of skincare products, jointly announced that they had entered into a merger agreement pursuant to which the companies would seek to merge. Under the terms of the Merger Agreement, Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.
The Company allegedly made false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading.
If you are an RVNC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose: (i) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (ii) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (iii) that, as a result, Regeneron offered a price concession that lowered Eylea's selling price; (iv) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (v) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (vi) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (vii) that, as a result of the foregoing, the Company's positive statements about the its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are an REGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
BioAge Labs, Inc. (NASDAQ:BIOA)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information regarding the Company's IPO. BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share. However, less than three months later, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. In response to the news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
Allegedly, investors bought BioAge stock in the initial public offering based on false and/or materially misleading information concerning its STRIDES Phase 2 clinical trial and these investors sustained damages as a result thereof.
If you are a BIOA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com
SOURCE: Lifshitz Law PLLC
View the original
press release on ACCESS Newswire
